Dalifer Freites-Núñez1, Athan Baillet2, Luis Rodriguez-Rodriguez3, Minh Vu Chuong Nguyen2, Isidoro Gonzalez4, Jose Luis Pablos5, Alejandro Balsa6, Monica Vazquez7, Philippe Gaudin2, Benjamín Fernandez-Gutierrez1. 1. Rheumatology Department and Health Research Institute, Hospital Clinico San Carlos, Madrid, Spain. 2. Department of Rheumatology, CHU Grenoble, Échirolles, France. 3. Rheumatology Department and Health Research Institute, Hospital Clinico San Carlos, Madrid, Spain. lrrodriguez@salud.madrid.org. 4. Rheumatology Department and Health Research Institute, Hospital Universitario La Princesa, Madrid, Spain. 5. Rheumatology Department and Health Research Institute, Hospital Universitario 12 de Octubre, Madrid, Spain. 6. Rheumatology Department and Health Research Institute, Hospital Universitario La Paz, Madrid, Spain. 7. Rheumatology Department and Health Research Institute, Hospital Universitario Ramon y Cajal, Madrid, Spain.
Abstract
BACKGROUND: Rheumatoid arthritis (RA) is one of the leading chronic inflammatory rheumatism. First-line therapy with synthetic disease-modifying antirheumatic drugs (sDMARD) is insufficiently effective in 40% of cases and these patients are treated with biotherapies. The increased use of these drugs each year is becoming a public health issue with considerable economic burden. This cost is 20 times higher than that of sDMARD. However, among patients treated with biotherapies, clinical practice shows that about one third will not respond to the selected drug. In nonresponse cases, practitioners currently have no choice but to perform an empirical switching between different treatments, because no tool capable of predicting the response or nonresponse to these molecules is currently available. METHODS: The study is a prospective, phase III, controlled, multicenter, and randomized, single-blind (patient) clinical trial, including RA patients with a previous failure to anti-TNF therapies. The main objective is the analysis of the clinical and pharmacoeconomic impact after 6 months of treatment. Intervention arm: prescription of biotherapy (rituximab, adalimumab, abatacept) using SinnoTest® software, a prediction software based on proteomic biomarkers. Control arm: prescription of biotherapy based on current practice, without the SinnoTest® software (any biotherapy). In addition, a substudy will be carried out within this trial to generate a biobank and further analyze the proteomic profile of the patients and their modification throughout the study. DISCUSSION: This clinical trial study will be the first validation study of a biotherapy response prediction software, bringing personalized medicine into the management of RA. We expect that the findings from this study will bring several benefits for the patient and the Health Care System. TRIAL REGISTRATION: ClincalTrials.gov NCT04147026 . Registered on 31 October, 2019.
RCT Entities:
BACKGROUND:Rheumatoid arthritis (RA) is one of the leading chronic inflammatory rheumatism. First-line therapy with synthetic disease-modifying antirheumatic drugs (sDMARD) is insufficiently effective in 40% of cases and these patients are treated with biotherapies. The increased use of these drugs each year is becoming a public health issue with considerable economic burden. This cost is 20 times higher than that of sDMARD. However, among patients treated with biotherapies, clinical practice shows that about one third will not respond to the selected drug. In nonresponse cases, practitioners currently have no choice but to perform an empirical switching between different treatments, because no tool capable of predicting the response or nonresponse to these molecules is currently available. METHODS: The study is a prospective, phase III, controlled, multicenter, and randomized, single-blind (patient) clinical trial, including RApatients with a previous failure to anti-TNF therapies. The main objective is the analysis of the clinical and pharmacoeconomic impact after 6 months of treatment. Intervention arm: prescription of biotherapy (rituximab, adalimumab, abatacept) using SinnoTest® software, a prediction software based on proteomic biomarkers. Control arm: prescription of biotherapy based on current practice, without the SinnoTest® software (any biotherapy). In addition, a substudy will be carried out within this trial to generate a biobank and further analyze the proteomic profile of the patients and their modification throughout the study. DISCUSSION: This clinical trial study will be the first validation study of a biotherapy response prediction software, bringing personalized medicine into the management of RA. We expect that the findings from this study will bring several benefits for the patient and the Health Care System. TRIAL REGISTRATION: ClincalTrials.gov NCT04147026 . Registered on 31 October, 2019.
Authors: S B Krintel; C Dehlendorff; M L Hetland; K Hørslev-Petersen; K K Andersen; P Junker; J Pødenphant; T Ellingsen; P Ahlquist; H M Lindegaard; A Linauskas; A Schlemmer; M Y Dam; I Hansen; H C Horn; A Jørgensen; J Raun; C G Ammitzbøll; M Østergaard; K Stengaard-Pedersen; J S Johansen Journal: Pharmacogenomics J Date: 2015-05-05 Impact factor: 3.550
Authors: C Trocmé; H Marotte; A Baillet; B Pallot-Prades; J Garin; L Grange; P Miossec; J Tebib; F Berger; M J Nissen; R Juvin; F Morel; P Gaudin Journal: Ann Rheum Dis Date: 2008-07-29 Impact factor: 19.103
Authors: Bodhayan Prasad; Cathy McGeough; Amanda Eakin; Tan Ahmed; Dawn Small; Philip Gardiner; Adrian Pendleton; Gary Wright; Anthony J Bjourson; David S Gibson; Priyank Shukla Journal: PLoS Comput Biol Date: 2022-07-05 Impact factor: 4.779